Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 238 participants.

Also called NCT07715279

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 238 participants (planned count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as a collaborator
  • West China Hospital Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07715279
  • ChiCTR ChiCTR2500108507
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07715279. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-24 (actual); primary completion 2029-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression
Acronym
VERIFICATION
Condition
Calcific Aortic Valve Disease
Condition
AORTIC VALVE DISEASES
Condition
Aortic Valve Stenosis
Intervention (Drug)
Vericiguat (BAY1021189)
Intervention (Drug)
Placebo
Lead sponsor
West China Hospital (class: other)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct07715279
Content hash
58ff36526e8430abf02c5f09cfc8d9d492edda097cca0f2398e12017495feffa